

Biotransformations from and to methylated flavonoids

Subtitle

Benjamin Weigel
Leibniz-Institute of Plant Biochemistry
Department of Bioorganic Chemistry
Weinberg 3
06120 Halle(Saale)
May 8, 2015

Advisor: Prof. Dr. Ludger A. Wessjohann
wessjohann@ipb-halle.de
+49 (345) 5582-1301

noch nicht bekannt

1 **Contents**

2	Notes of Revisors	viii
3	I Preface	1
4	<hr/>	
5	1 Abstracts	2
6	1.1 English Abstract	2
7	1.2 Deutsche Zusammenfassung	2
8	II Thesis	3
9	<hr/>	
10	2 Introduction	4
11	2.1 Natural products and secondary metabolites	4
12	2.1.1 General.	4
13	2.1.2 Classes of natural products	4
14	2.2 Alkylating reactions in nature	4
15	2.2.1 Methylation	4
16	2.2.2 Prenylation	4
17	2.2.3 Glycosylation	5
18	2.3 Usage and expansion of natures reaction toolbox	5
19	2.3.1 Terpene synthases and elongases	5
20	2.3.2 Methyl transferases.	5
21	2.3.3 Glycosyl transferases.	5
22	2.3.4 Other important enzymes in biotech research.	5
23	2.4 Conclusion	5

1	3 Material And Methods	6
2	3.1 Materials	6
3	3.1.1 Chemicals	6
4	3.1.2 Commonly used solutions and buffers	6
5	3.1.3 Culture media used to grow bacteria	7
6	3.1.4 Bacterial strains	7
7	3.1.5 Plasmids	9
8	3.1.6 Oligonucleotides and synthetic genes	9
9	3.1.7 Instruments	10
10	3.1.8 Software	10
11	3.2 Microbiology.	10
12	3.3 Molecular Biology.	11
13	3.3.1 Golden Gate Cloning	11
14	3.3.2 Subcloning of genes	11
15	3.4 Protein biochemistry	12
16	3.4.1 Protein production test (expression test).	12
17	3.4.2 Protein subfractionation	12
18	3.4.3 Protein sample concentration by TCA precipitation	13
19	3.4.4 Preparation of periplasmic protein	13
20	3.4.5 Discontinuous SDS-polyacrylamide gel electrophoresis (SDS-	
21	PAGE)	14
22	3.4.6 Buffer change of protein samples	14
23	3.4.7 Production of recombinant protein	14
24	3.4.8 Preparation of inclusion bodies (IBs).	15
25	3.4.9 Purification of His-tagged proteins using immobilized metal	
26	affinity chromatography (IMAC)	16
27	3.5 Crystallographic Procedures	16
28	3.5.1 Crystallization of proteins	16
29	3.5.2 Data collection and processing	17
30	3.5.3 Structure solution.	17
31	3.5.4 Model building, refinement and validation.	18
32	3.5.5 <i>In silico</i> substrate docking	18
33	3.6 Analytics	18
34	3.6.1 In vitro determination of glucose	19
35	3.6.2 HPLC measurements	19
36	4 Evaluation of PFOMT towards the acceptance of long-chain SAM	
37	analogues	21
38	4.1 Introduction	21
39	4.2 Substrate binding studies using ITC.	21

1	4.3	Determination of the structure of <i>apo</i> -PFOMT.	21
2	4.3.1	PFOMT activity in deep eutectic solvents (DES) / Solubility- enhancing effects of DES.	21
3	4.4	Study of variants for long-chain alkylations	21
4	4.4.1	PFOMT-Paper (DIM)	21
5	4.4.2	Dockings???	21
6	4.5	Colclution/Discussion	21
7			
8	5	Enzymatic methylation of Non-catechols	22
9	5.1	Introduction	22
10	5.2	SOMT-2.	22
11	5.2.1	In vivo methylation studies using <i>N. benthamiana</i>	22
12	5.2.2	In vivo studies in <i>E. coli</i>	22
13	5.2.3	In vitro studies using recombinantly produced SOMT-2	22
14	5.3	PFOMT	22
15	5.3.1	Acidity and Nucleophilicity of phenolic hydroxyl-groups	22
16	5.3.2	pH-Profiles of PFOMT-catalysis	22
17	5.3.3	Influence of Mg ²⁺ on PFOMT activity	22
18	5.4	Consensus or Bioinformatic points-of-view (COMT)???	22
19	5.5	Conclusion/Discussion	22
20	6	Development of an whole cell methyl transferase screening sys- tem	23
21	6.1	Introduction	23
22	6.2	Theoretical considerations / design of system	23
23	6.3	Detectability of S-adenosyl-L-homocysteine (SAH)	23
24	6.4	Usage of the <i>lsr</i> -promoter for true autoinduction	23
25	6.5	Conclusion/Discussion	23
26			
27	7	DES in protein crystallography	24
28	7.1	Introduction	24
29	7.2	Solubility enhancement of hydrophobic substances by addition of DES	24
30	7.3	Enzymatic O-methylation in DES	24
31	7.4	DES as precipitants in protein crystallization	24
32	7.5	Conclusion/Discussion	24
33			
34	8	Acknowledgements	25

¹	III Appendix	26
²	<hr/>	
³	A Figures	27
⁴	B Tables	28
⁵	C Affidavit	30
⁶	Acronyms	35
⁷	Glossary	37





¹**List of Figures**

²	3.1 GOD assay	20
³	A.1 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean com-	
⁴	modo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus	
⁵	et magnis dis parturient montes, nascetur ridiculus mus. Donec quam	
⁶	felis, ultricies nec, pellentesque eu, pretium quis, sem.	27

¹ **List of Tables**

²	3.1 NADES-mixtures	7
³	3.3 Plasmids used in this work.	9
⁴	3.4 Primers used in this work. Recognition sites for endonucleases are	
⁵	underlined. Positions used for site directed mutagenesis are in lower	
⁶	case font.	9
⁷	B.1 Overview over the constructs produced for the present thesis. Each step	
⁸	during the production of the construct is given in the workflow steps	
⁹	column. Primers (<i>italic font</i>) or restriction sites used during each step	
¹⁰	are displayed in parenthesis.	29

¹ **Notes of Revisors**

²	 BWEIGEL: Überprüfen!	15
³	 BWEIGEL: nochma genau guckn	17
⁴	 BWEIGEL: add DES crystallization	17
⁵	 BWEIGEL: Lysozym struktur	18

1

2

I

Preface


1 Abstracts

1.1 English Abstract

Test Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut purus elit, vestibulum ut, placerat ac, adipiscing vitae, felis. Curabitur dictum gravida mauris. Nam arcu libero, nonummy eget, consectetur id, vulputate a, magna. Donec vehicula augue eu neque. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Mauris ut leo. Cras viverra metus rhoncus sem. Nulla et lectus vestibulum urna fringilla ultrices. Phasellus eu tellus sit amet tortor gravida placerat. Integer sapien est, iaculis in, pretium quis, viverra ac, nunc. Praesent eget sem vel leo ultrices bibendum. Aenean faucibus. Morbi dolor nulla, malesuada eu, pulvinar at, mollis ac, nulla. Curabitur auctor semper nulla. Donec varius orci eget risus. Duis nibh mi, congue eu, accumsan eleifend, sagittis quis, diam. Duis eget orci sit amet orci dignissim rutrum.

1.2 Deutsche Zusammenfassung

Nam dui ligula, fringilla a, euismod sodales, sollicitudin vel, wisi. Morbi auctor lorem non justo. Nam lacus libero, pretium at, lobortis vitae, ultricies et, tellus. Donec aliquet, tortor sed accumsan bibendum, erat ligula aliquet magna, vitae ornare odio metus a mi. Morbi ac orci et nisl hendrerit mollis. Suspendisse ut massa. Cras nec ante. Pellentesque a nulla. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Aliquam tincidunt urna. Nulla ullamcorper vestibulum turpis. Pellentesque cursus luctus mauris.



Thesis

1

2

¹ 2 Introduction

² Some introductory text

³ 2.1 Natural products and secondary metabolites

⁴ 2.1.1 General

⁵ 2.1.2 Classes of natural products

⁶ Terpenoids and Steroids

⁷ ... here is some text

⁸ Polyketides and non-ribosomal peptides

⁹ ... here is some text

¹⁰ Alkaloids

¹¹ ... here is some text

¹² Phenylpropanoids

¹³ ... here is some text

¹⁴ 2.2 Alkylating reactions in nature

¹⁵ 2.2.1 Methylation

¹⁶ 2.2.2 Prenylation

¹ 2.2.3 Glycosylation

² 2.3 Usage and expansion of nature's reaction toolbox
³

⁴ 2.3.1 Terpene synthases and elongases

⁵ 2.3.2 Methyl transferases

⁶ 2.3.3 Glycosyl transferases

⁷ 2.3.4 Other important enzymes in biotech research

⁸ BMVOs

⁹ Esterases/Lipases

¹⁰ Oxidases

¹¹ Lyases

¹² Transaminases

¹³ 2.4 Conclusion

3 Material And Methods

Within this section percentages refer to volume per volume (v/v) percentages unless otherwise specified.

3.1 Materials

3.1.1 Chemicals

Enzymes and buffers used for molecular cloning were obtained from Life Technologies (Darmstadt, Germany), unless otherwise noted. Flavonoid HPLC standards were purchased from Extrasynthese (Genay, France). Deuterated solvents were aquired from Deutero GmbH (Kastellaun, Germany). Solvents, purchased from VWR (Poole, England), were distilled in-house before use. All other chemicals were obtained from either Sigma-Aldrich (Steinheim, Germany), Applichem (Darmstadt, Germany), Carl Roth (Karlsruhe, Germany) or Merck (Darmstadt, Germany).

3.1.2 Commonly used solutions and buffers

50× 5052	25 % glycerol, 2.5 % (w/v) glucose, 10 % (w/v) α-lactose
binding buffer	50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 2.5 mM imidazole pH 7
elution buffer	50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 250 mM imidazole pH 7
lysis buffer	50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 2.5 mM imidazole, 0.2 % Tween-20 pH 7
1 M MMT pH 4 (10×)	26.8 g/l L-malic acid, 78.1 g/l MES, 26.8 g/l Tris, 2.1 % 10 M HCl
1 M MMT pH 9 (10×)	26.8 g/l L-malic acid, 78.1 g/l MES, 26.8 g/l Tris, 6.7 % 10 M NaOH
20× NPS	1 M Na ₂ HPO ₄ , 1 M KH ₂ PO ₄ , 0.5 M (NH ₄) ₂ SO ₄

5× SDS sample buffer	10 % (w/v) SDS, 10 mM β-mercapto ethanol, 20 % glycerol, 0.2 M Tris/HCl pH 6.8, 0.05 % (w/v) bromophenolblue
1000× trace elements	50 mM FeCl ₃ , 20 mM CaCl ₂ , 10 mM MnCl ₂ , 10 mM ZnSO ₄ , 2 mM CoCl ₂ , 2 mM CuCl ₂ , 2 mM NiCl ₂ , 2 mM Na ₂ MoO ₄ , 2 mM Na ₂ SeO ₃ , 2 mM H ₃ BO ₃

1 **Preparation of deep eutectic solvents (DES)**

2 Deep eutectic solvents (DES) were prepared by adding each component in a round-
3 bottom flask with a stirrer and stirring the mixture at 50 °C with intermittent
4 sonication treatments until a clear solution was obtained.

Table 3.1.: NADES-mixtures

name	composition	mole ratio	mass fraction (w/w)
PCH	propane-1,2-diol	1:1:1	0.326
	choline chloride		0.597
	water		0.077
GCH	D-glucose	2:5:5	0.314
	choline chloride		0.608
	water		0.078

5 **3.1.3 Culture media used to grow bacteria**

LB-medium	10 g/l NaCl, 10 g/l tryptone, 5 g/l yeast extract, pH 7.5
LB-agar	LB + 1.5 % (w/v) agar-agar
TB-medium	12 g/l tryptone, 24 g/l yeaxst extract, 0.4 % glycerol, 72 mM K ₂ HPO ₄ , 17 mM KH ₂ PO ₄
ZY	10 g/l tryptone, 5 g/l yeast extract
ZYP-5052	in proportions: 0.928 ZY, 0.05 20× NPS, 0.02 50× 5052, 0.002 1 M MgSO ₄ , 0.0002 1000× trace elements

6 **3.1.4 Bacterial strains**

7 ***E.coli***

BL21(DE3)	F ⁻ <i>ompT hsdSB(r_B⁻,m_B⁻) gal dcm</i> λ(DE3) Invitrogen, Karlsruhe (Germany)
C41(DE3)	F ⁻ <i>ompT hsdSB(r_B⁻,m_B⁻) gal dcm</i> λ(DE3) Lucigen, Wisconsin (USA)
C43(DE3)	F ⁻ <i>ompT hsdSB(r_B⁻,m_B⁻) gal dcm</i> λ(DE3) Lucigen, Wisconsin (USA)
DH5α	F ⁻ Φ80 <i>lacZ</i> ΔM15 Δ(<i>lacZYA-argF</i>) U169 <i>recA1 endA1 hsdR17</i> (r _K ⁻ m _K ⁺) <i>phoA supE44</i> λ ⁻ <i>thi-1</i> <i>gyrA96</i> <i>relA1</i> Invitrogen, Karlsruhe (Germany)
JM110	<i>rpsL thr leu thi lacY galK galT ara tonA tsx dam dcm glnV44</i> Δ(<i>lac-proAB</i>) e14- [F' <i>traD36 proAB⁺ lacI^q lacZ</i> ΔM15] <i>hsdR17</i> (r _K ⁻ m _K ⁺) Martin-Luther-University Halle-Wittenberg
JW1593 (BW25113 derivative)	<i>rrnB</i> Δ <i>lacZ</i> 4787 <i>HsdR</i> 514 Δ(<i>araBAD</i>)568 <i>rph-1</i> Δ <i>ydgG</i> (Kan ^R) Keio Collection, National Institute of Genetics (Japan)
MG1655	F ⁻ λ ⁻ <i>ilvG⁻ rfb-50 rph-1</i> DSMZ, Hamburg (Germany)
One Shot TOP10	F ⁻ Φ80 <i>lacZ</i> ΔM15 Δ(<i>mrr-hsdRMS-mcrBC</i>) <i>recA1 endA1 mcrA</i> Δ <i>lacX74</i> <i>araD139</i> Δ(<i>ara-leu</i>)7697 <i>galU galK rpsL</i> (Str ^R) λ ⁻ <i>nupG</i> Invitrogen, Karlsruhe (Germany)
Origami(DE3)	Δ(<i>ara-leu</i>)7697 Δ <i>lacX74</i> Δ <i>phoA</i> <i>Pvull phoR</i> <i>araD139 ahpC galE galK rpsL</i> F'[<i>lac + lacI q pro</i>] (DE3) <i>gor522::Tn10 trxB</i> (Kan ^R , Str ^R , Tet ^R) Novagen, Wisconsin (USA)
Rosetta(DE3)	F ⁻ <i>ompT hsdSB(r_B⁻,m_B⁻) gal dcm</i> λ(DE3) pRARE (Cam ^R) Novagen, Wisconsin (USA)
Rosetta(DE3) pLysS	F ⁻ <i>ompT hsdSB(r_B⁻,m_B⁻) gal dcm</i> λ(DE3) pLysSRARE (Cam ^R) Novagen, Wisconsin (USA)
T7 Express	<i>fhuA2 lacZ::T7 gene1 [lon] ompT gal sulA11 R(mcr-73::miniTn10-Tet^S)2 [dcm] R(zgb-210::Tn10-Tet^S) endA1</i> Δ(<i>mcrC-mrr</i>)114::IS10 NEB, Massachusetts (USA)

¹ *Agrobacterium tumefaciens*

GV3101	chromosomal background: C58, marker gene: <i>rif</i> , Ti-plasmid: cured, opine: nopaline Sylvestre Marillonet, IPB
--------	--

3.1.5 Plasmids

Table 3.3.: Plasmids used in this work.

name	supplier/source
pACYCDuet-1	Merck, Darmstadt (Germany)
pCDFDuet-1	Merck, Darmstadt (Germany)
pET-20b(+)	Merck, Darmstadt (Germany)
pET-28a(+)	Merck, Darmstadt (Germany)
pET-32a(+)	Merck, Darmstadt (Germany)
pET-41a(+)	Merck, Darmstadt (Germany)
pQE30	QIAGEN, Hilden (Germany)
pUC19	Invitrogen, Karlsruhe (Germany)

3.1.6 Oligonucleotides and synthetic genes

Oligonucleotides and primers were ordered from Eurofins Genomics (Ebersberg, Germany). The purity grade was *high purity salt free* (HPSF). Synthetic genes or gene fragments were obtained from GeneArt® (Life Technologies, Darmstadt, Germany) or Eurofins Genomics (Ebersberg, Germany).

Table 3.4.: Primers used in this work. Recognition sites for endonucleases are underlined. Positions used for site directed mutagenesis are in lower case font.

name	sequence (5'→3')	cloning site
somt1	TTG <u>AAG ACA</u> AAA TGG CTT CTT CAT TAA ACA ATG GCC G	BpiI
somt2	TTG <u>AAG ACA</u> AGG ACA CCC CAA ATA CTG TGA GAT CTT CC	BpiI
somt3	TTG <u>AAG ACA</u> AGT CCT TAG GAA CAC CTT TCT GGG AC	BpiI
somt4	TTG <u>AAG ACA</u> AAA GCT CAA GGA TAG ATC TCA ATA AGA GAC	BpiI
pfomt1.fw	CAG AGA GGC cTA TGA GAT TGG CTT GC	
pfomt1.rv	GCA AGC CAA TCT CAT AgG CCT CTC TG	
pfomt2.fw	<u>CAT ATG</u> GAT TTT GCT GTG ATG AAG CAG GTC	NdeI
pfomt2.rv	<u>GAA TTC</u> AAT AAA GAC GCC TGC AGA AAG TG	EcoRI
pRha1.fw	CTC TAG <u>CAG ATC</u> <u>TCG</u> GTG AGC ATC ACA TCA CCA CAA TTC	BglII
pRha1.rv	CAA TTG <u>AGG ATC</u> <u>CCC</u> ATT TTA ACC TCC TTA GTG	BamHI
pUC1.fw	GCG TAT TGG Gag aTC TTC CGC TTC CTC	
pUC1.rv	GAG GAA GCG GAA GAt ctC CCA ATA CGC	

1 3.1.7 Instruments

CD-spectrometer	Jasco J-815 (Eaton, USA)
electrophoresis (horizontal)	Biometra Compact XS/S (Göttingen, Germany)
electrophoresis (vertical)	Biometra Compact M (Göttingen, Germany) Biometra Minigel-Twin (Göttingen, Germany)
FPLC	ÄKTA purifier (GE Healthcare, Freiburg, Germany)
GC/MS	GC-MS-QP2010 Ultra (Shimadzu, Duisburg, Germany)
HPLC	VWR-Hitachi LaChrom Elite (VWR, Darmstadt, Germany)
ITC	MicroCal iTC200 (Malvern, Worcestershire, UK)
plate-reader	SpectraMax M5 (Molecular Devices, Biberach, Germany)
NMR-spectrometer	Varian Unity 400 (Agilent, Böblingen, Germany) Varian VNMRS 600 (Agilent, Böblingen, Germany)
photospectrometer	Eppendorf Biophotometer Plus (Hamburg, Germany) JASCO V-560 (Eaton, USA) Colibri Microvolume Spectrometer (Biozym, Hess. Oldendorf, Germany)
centrifuges	Eppendorf 5424 (Hamburg, Germany) Hettich Mikro 120 (Kirchlengern, Germany) Beckman Avanti J-E, Beckman Allegra X-30R (Krefeld, Germany)
centrifuge rotors	Beckman JA-10, JA-16.250, JS-4.3 (Krefeld, Germany)

2 3.1.8 Software

3 All mathematical and statistical computations and graphics were done with the R
4 software (versions 3.1.X, <http://cran.r-project.org/>) [25]. Visualizations of macro-
5 molecules were arranged using the PyMol Molecular Graphics System, version
6 1.7.0.0 (Schrödinger, New York, USA).
7 Physicochemical calculations and calculations of different molecular descriptors
8 were performed using Marvin Beans 15.4.13.0 (ChemAxon, Budapest, Hungary) and
9 Molecular Operating Environment 2008.10 (Chemical Computing Group, Montreal,
10 Canada). Special software used for X-ray crystal structure solution is discussed
11 separately in the corresponding section (3.5).

12 3.2 Microbiology

3.3 Molecular Biology

Basic molecular biology methods like polymerase chain reaction (PCR), DNA restriction/ligation, DNA gel electrophoresis, preparation of competent cells and transformation were performed based on the protocols summarized by Sambrook and Russell [31].

Plasmid DNA was isolated using the QIAprep® Spin Miniprep Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions.

In vitro site-directed mutagenesis was set-up according to the protocol of the QuikChange™ Site-Directed Mutagenesis kit [2] offered by Agilent Technologies (Santa Clara, USA).

Nucleotide fragments obtained by PCR, restriction/ligation procedures or excision from electrophoresis gels were purified and concentrated using the Nucleospin Gel and PCR Clean-up kit provided by Machery-Nagel (Düren, Germany) according to the instructions provided by the manufacturer.

3.3.1 Golden Gate Cloning

The Golden Gate cloning procedure is a one-pot method, meaning the restriction digestion and ligation are carried out in the same reaction vessel at the same time [14, 7]. Consequently PCR-fragments, destination vector, restriction endonuclease and ligase are added together in this reaction. The methodology employs type II restriction enzymes, which together with proper design of the fragments allow for a ligation product lacking the original restriction sites.

For digestion/ligation reactions of fragments containing BpiI sites, 20 fmol of each fragment or vector, together with 5 U of BpiI and 5 U of T4 ligase were combined in a total volume of 15 µl 1× ligase buffer. For fragments to be cloned via BsaI sites, BpiI in the above reaction was substituted by 5 U BsaI.

The reaction mixture was placed in a thermocycler and incubated at 37 °C for 2 min and 16 °C for 5 min. These two first steps were repeated 50 times over. Finally, the temperature was raised to 50 °C (5 min) and 80 °C (10 min) to inactivate the enzymes.

3.3.2 Subcloning of genes

All subcloning procedures were performed according to section 3.3 and specifically subsection 3.3.1. Specific steps for the subcloning of any genes discussed can be found in the appendix (p.29). The *pfomt* gene was subcloned from the pQE-30 vector kindly provided by Thomas Vogt (Leibniz-Institute of Plant Biochemistry (IPB), Halle, Germany) into the pET-28a(+) vector. The *somt-2* gene was subcloned

¹ from the pQE-30 vector kindly provided by Martin Dippe (IPB, Halle, Germany)
² into the pET-28-MC vector.

³ 3.4 Protein biochemistry

⁴ Stock solutions of antibiotics, IPTG or sugars were prepared according to the pET
⁵ System Manual by Novagen [Novagen2011], unless otherwise noted.

⁶ 3.4.1 Protein production test (expression test)

⁷ The heterologous production of proteins in *E. coli* was assessed in a small scale
⁸ protein production test, henceforth called expression test. Single colonies of *E. coli*
⁹ transformed with the constructs to be studied were used to inoculate a 2 ml starter
¹⁰ culture in lysogeny broth (LB)-medium containing the appropriate antibiotics. The
¹¹ concentrations of antibiotics used was as follows: 200 µg/ml ampicillin, 150 µg/ml
¹² kanamycin, 50 µg/ml chloramphenicol, 20 µg/ml tetracycline.

¹³ The starter culture was allowed to grow at 37 °C and 200 rpm over night. A 5 ml
¹⁴ sampling culture of the medium to be studied containing the appropriate antibiotics
¹⁵ was prepared. The media tested included LB, terrific broth (TB) and auto-induction
¹⁶ media like ZYP-5052. The sampling culture was inoculated to an OD⁶⁰⁰ of 0.075
¹⁷ using the starter culture and incubated at different temperatures and 200 rpm in
¹⁸ a shaking incubator. 1 mM isopropyl-D-thiogalactopyranosid (IPTG) was added
¹⁹ when the OD⁶⁰⁰ reached 0.6-0.8, if appropriate for the studied construct. 1 ml
²⁰ samples were removed after different times of incubation (e.g. 4, 8, 12 hours),
²¹ subfractionated (3.4.2) and analyzed via SDS-polyacrylamide gel electrophoresis
²² (PAGE) (3.4.5).

²³ Exact specifications of growth conditions (e.g. temperature, time, constructs) are
²⁴ discussed in the individual sections.

²⁵ 3.4.2 Protein subfractionation

²⁶ The protein subfractionation procedure described herein was adapted from the pro-
²⁷ tocol described in the pET Manual [Novagen2011]. Overall 5 protein subfractions
²⁸ can be obtained, including *total cell protein*, *culture supernatant (medium) protein*,
²⁹ *periplasmic protein*, *soluble cytoplasmic protein* and *insoluble protein*.

³⁰ The OD⁶⁰⁰ of the culture sample was measured and the cells harvested by centrif-
³¹ gation at 10000 × g, 4 °C for 5 minutes. The protein in the supernatant medium was
³² concentrated by precipitation with trichloro acetic acid (TCA) (3.4.3) for SDS-PAGE
³³ analysis. The periplasmic protein was prepared (3.4.4) and also concentrated by

TCA precipitation for SDS-PAGE. Cells were lysed by resuspending the cell pellet in $(OD^{600} \times V \times 50) \mu\text{l}$ of bacterial protein extraction reagent (B-PER) and vortexing vigorously for 30 s. The suspension was incubated at room temperature (RT) for 30 min to assure complete lysis. To separate insoluble protein and cell debris from the soluble cytosolic protein, the suspension was centrifuged at $10000 \times g$ and 4°C for 10 min. Soluble cytoplasmic protein was contained in the supernatant, whereas insoluble protein remained in the pellet. For SDS-PAGE analysis of the insoluble protein, the pellet was resuspended in the same volume of B-PER. To obtain only the total cell protein fraction, the preparation of periplasmic and soluble cytosolic protein was omitted. Sample volumes of $10 \mu\text{l}$ of each fraction were used for SDS-PAGE analysis.

3.4.3 Protein sample concentration by TCA precipitation

Diluted protein samples were concentrated by TCA precipitation in microcentrifuge tubes. Therefore 0.1 volume (V) of 100% (w/v) TCA in water was added to the clarified sample, which was then vortexed for 15 s and placed on ice for a minimum of 15 min. The sample was centrifuged at $14000 \times g$, 4°C for 15 min. The supernatant was discarded and the pellet was washed twice with 0.2 V ice-cold acetone. The acetone was removed and the pellet set to air-dry in an open tube. After drying, the protein pellet was resuspended in 0.1 V phosphate buffered saline (PBS) containing $1 \times \text{SDS-sample buffer}$ by heating to 85°C and vigorous vortexing, to achieve a $10 \times$ concentration. After resuspension the sample was analyzed by SDS-PAGE or stored at -20°C until use.

3.4.4 Preparation of periplasmic protein

Target proteins may be directed to the periplasmic space by N-terminal signal sequences like *pelB* or *DsbA/C* [17]. The periplasm is, other than the cytosol, an oxidizing environment and often used for the production of proteins containing disulfide linkages. The preparation of periplasmic protein was accomplished by an osmotic shock protocol modified from Current Protocols in Molecular Biology [3]. The cell pellet was resuspended in the same volume as the culture sample of 30 mM tris-HCl , 20% (w/v) sucrose, $\text{pH } 8$ and $1 \text{ mM ethylenediaminetetraacetic acid (EDTA)}$ was added. The suspension was stirred for 10 min at RT and the cells were collected by centrifugation at $10000 \times g$, 4°C for 10 min. The supernatant was discarded and the cell pellet was resuspended in the same volume of ice-cold 5 mM MgSO_4 . The suspension was stirred for 10 min on ice, while the periplasmic proteins were released into the solution. The cells were collected by centrifugation as before. Periplasmic proteins were contained in the supernatant.

3.4.5 Discontinuous SDS-polyacrylamide gel electrophoresis (SDS-PAGE)

The analysis of samples via SDS-PAGE was realized via the discontinuous system first described by Laemmli, which allows separation of proteins based on their electrophoretic mobility, which in turn depends on their size [16]. The SDS-PAGE procedure was carried out according to standard protocols described by Sambrook and Russell [31]. Very dilute and/or samples with high ionic strength were concentrated and/or desalted by the TCA precipitation procedure described in subsection 3.4.3. Generally a 10 % (acrylamide/bisacrylamide) running gel combined with a 4 % stacking gel was used. Reducing SDS-PAGE sample buffer was added to the protein sample to be analyzed, whereafter the sample was heated to 95 °C for 5 min, to allow for total unfolding of the protein. After cooling to RT the samples were transferred into the gel pockets for analysis. The *PageRuler™ Prestained Protein Ladder* (Life Technologies GmbH, Darmstadt, Germany) was used as a molecular weight (MW) marker and run alongside every analysis as a reference. Gels were stained using a staining solution of 0.25 % Coomassie Brilliant Blue G-250 (w/v) in water:methanol:acetic acid (4:5:1) and destained by treatment with water:methanol:acetic acid (6:3:1).

3.4.6 Buffer change of protein samples

The buffer in protein samples was exchanged either by dialysis, or by centrifugal filter concentrators (Amicon® Ultra Centrifugal Filter; Merck, Darmstadt, Germany). Large volumes of highly concentrated protein solutions were preferably dialyzed. Respectively, very dilute samples were concentrated and rebuffed using centrifugal concentrators. Dialysis was carried out at least twice against a minimum of 100 times the sample volume. Dialysis steps were carried out at RT for 2 hours, or over-night at 4 °C. Centrifugal concentrators were used according to the manufacturers instructions.

3.4.7 Production of recombinant protein

Heterologous production of PFOMT

Phenylpropanoid and flavonoid O-methyl transferase (PFOMT) was produced as a N-terminally (His)₆-tagged fusion protein. A 2 ml starter culture of LB containing 100 µg/ml kanamycin was inoculated with a single colony of *E. coli* BL21(DE3) transformed with pET28-pfomt and incubated at 37 °C, 220 rpm for 6 hours. The main culture (N-Z-amine, yeast extract, phosphate (ZYP-5052) containing 200 µg/ml

kanamycin) was inoculated with the starter culture such that OD^{600} was 0.05. The culture was incubated in a shaking incubator at 37 °C, 220 rpm over night (≈ 16 h). Due to the autoinducing nature of the ZYP-5052 medium, addition of IPTG was not necessary. Cells were harvested by centrifugation at $10000 \times g$, 4 °C for 10 min and the supernatant discarded. The pellet was resuspended in 50 mM Tris/HCl, 500 mM NaCl, 2.5 mM imidazole, 10 % glycerol pH 7 using a volume of ≈ 10 ml/g of cell pellet. The cells were lysed by sonication (70 % amplitude, 1 s on-off-cycle) for 30 seconds, which was repeated twice. The crude lysate was clarified by centrifugation at $15000 \times g$, 4 °C for 15 minutes followed by filtration through a 0.45 μ m filter. Consequently, the His-tagged PFOMT was purified by immobilized metal affinity chromatography (IMAC) (3.4.9). The eluted PFOMT protein was dialyzed (3.4.6) against 25 mM HEPES, 100 mM NaCl, 5 % glycerol pH 7 and stored at -20 °C until use.

Heterologous production of SOMT-2

Soy O-methyl transferase (SOMT-2) was produced as a fusion protein with an N-terminal His-tag. A starter LB-culture (≈ 2 ml) containing 100 μ g/ml kanamycin was inoculated with a single colony of *E. coli* BL21(DE3) transformed with pET28MC-somt and incubated at 37 °C, 220 rpm for 6 hours. The starter culture was used to inoculate the main culture (LB-medium containing 100 μ g/ml kanamycin), such that $OD^{600} \approx 0.05$. The culture was incubated at 37 °C, 220 rpm in a shaking incubator until $OD^{600} \approx 0.6$. Expression was induced by addition of 1 mM IPTG. Incubation continued at 37 °C, 220 rpm for 6 hours. Cells were harvested by centrifugation ($10000 \times g$, 4 °C, 10 min) and used, or stored at -20 °C until use. SOMT-2 was produced in inclusion bodies (IBs), which were prepared as laid out in subsection 3.4.8.

BWEIGEL: Überprüfen!

3.4.8 Preparation of inclusion bodies (IBs)

Often, when recombinant protein is produced in high levels in *E. coli* it is accumulated in so-called inclusion bodies (IBs). The accumulating IBs consist mainly of the overproduced target protein, which is inherently quite pure already. IBs can be selectively recovered from *E. coli* cell lysates and can consequently be refolded. IBs were prepared according to a modified protocol by Palmer [23]. The cells were resuspended in 5 ml/g_{cells} IB lysis buffer (100 mM Tris/HCl, 5 mM EDTA, 5 mM DTT pH 7) and 5 mM benzamidine was added as protease inhibitor. The solution was homogenized using a tissue grinder homogenizer. 200 μ g/ml lysozyme was added to aid in the breakage of cells and the cells were lysed by sonicating thrice at 70 % amplitude (1 s on-off-cycle) for 30 seconds. The lysate was clarified by centrifuging for 1 h at $20000 \times g$, 4 °C. The supernatant was discarded

and the pellet was resuspended in 5 ml/g_{cells} IB wash buffer (100 mM Tris/HCl, 5 mM EDTA, 5 mM DTT, 2 M urea, 2 % (w/v) Triton X-100 pH 7), followed by thorough homogenization. The solution was centrifuged (30 min at 20000 × *g*, 4 °C), the supernatant discarded and the pellet was washed twice more. To remove detergent, the pellet was washed twice again. However, for this step the Triton X-100 was omitted from the IB-wash buffer. The IBs were resuspended in extraction buffer (100 mM Tris/HCl, 5 mM EDTA, 5 mM DTT, 8 M GdmCl pH 7) and stored at −20 °C until use.

3.4.9 Purification of His-tagged proteins using immobilized metal affinity chromatography (IMAC)

N- or C-terminal oligo-histidine tags (His-tags) are a common tool to ease purification of recombinantly produced proteins. The free electron pairs of the imidazole nitrogens of histidines can complex divalent cations such as Mg²⁺ or Ni²⁺, which are usually immobilized on a matrix of nitrilo triacetic acid (NTA)-derivatives. The affinity of the His-tag is correlated with its length and tagged proteins can simply be eluted by increasing the concentration of competing molecules (e.g. imidazole). His-tagged protein was purified by fast protein liquid chromatography (FPLC) via Ni²⁺- (HisTrap FF crude) or Co²⁺-NTA (HiTrap Talon FF crude) columns, obtained from GE Healthcare (Freiburg, Germany), following modified suppliers instructions. First the column was equilibrated with 5 column volumes (CV) of binding buffer (50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 2.5 mM imidazole pH 7). The sample (generally clarified lysate) was applied to the column using a flow of 0.75 ml/min. Unbound protein was removed by washing with 3 CV binding buffer. Unspecifically bound proteins were washed away by increasing the amount of elution buffer (50 mM Tris/HCl, 500 mM NaCl, 10 % glycerol, 250 mM imidazole pH 7) to 10 % (constant for 3 to 5 CV). Highly enriched and purified target protein was eluted with 6 to 10 CV of 100 % elution buffer.

3.5 Crystallographic Procedures

3.5.1 Crystallization of proteins

Commercially available crystallization screens were used to find initial crystallization conditions. The tested screens included kits available from Hampton Research (Aliso Viejo, USA) and Jena Bioscience (Jena, Germany). Crystallization screens were processed in 96-well micro-titer plate (MTP)s, where each well possessed 4 subwells aligned in a 2×2 matrix. The subwells were divided into 3 shallow

¹ wells for sitting drop vapour diffusion experimental setups and a fourth subwell,
² which was deep enough to act as buffer reservoir. This way the performance of
³ each crystallization buffer could be assessed using three different protein solutions
⁴ with varying concentrations, effectors etc. A pipetting robot (Cartesian Microsys,
⁵ Zinsser-Analystik; Frankfurt, Germany) was used to mix 200 nl of each, protein
⁶ and buffer solution, for a final volume of 400 nl. The crystallization preparations
⁷ were incubated at 16 °C and the progress of the experiment was documented by
⁸ an automated imaging-system (Desktop Minstrel UV, Rigaku Europe, Kent, UK).
⁹ Furthermore, fine screens (e.g. for refinement of crystallization conditions) were
¹⁰ set up by hand in 24-well MTPs using the hanging drop vapour diffusion method.

¹¹ PFOMT

¹² PFOMT protein was concentrated to (6 to 8) mg/ml and rebuffed to 10 mM
¹³ Tris/HCl pH 7.5 using Amicon[®] Ultracel centrifugal concentrators (10 kDa MWCO).
¹⁴ The concentrated protein solution was centrifuged at $14000 \times g$, 4 °C for 10 min to
¹⁵ remove any insoluble material or aggregates. Crystallization screens were set up
¹⁶ as described above.

¹⁷ PFOMT was crystallized using the following conditions 2 M $(\text{NH}_4)_2\text{SO}_4$, 20 % glycerol.
¹⁸ The protein solution contained 0.25 mM S-adenosyl-L-homocysteine (SAH),
¹⁹ 0.25 mM MgCl_2 , 0.25 mM ferulic acid and 7.53 mg/ml PFOMT.

BWEIGEL: nochma genau guckn

BWEIGEL: add DES crystallization

²¹ 3.5.2 Data collection and processing

²² Crystallographic data were collected at the beamline of the group of Professor
²³ Stubbs (MLU, Halle, Germany). The beamline was equipped with a rotating anode
²⁴ X-ray source MicroMax007 (Rigaku/MSD, Tokyo, Japan), which had a maximum
²⁵ power of 0.8 kW (40 kV, 20 mA) and supplied monochromatic $\text{Cu-K}\alpha$ -radiation with
²⁶ a wavelength of 1.5418 Å. Diffraction patterns were detected with a Saturn 944+
²⁷ detector (CCD++, Rigaku/MSD, Tokyo, Japan).

²⁸ Indexing and integration of the reflexes via Fourier transformation was accom-
²⁹ plished using *XDS* [12, 11, 13] or *MOSFLM* [24]. *Scala* [8], which is integrated in
³⁰ the Collaborative Computational Project No. 4 (CCP4)-Suite, was used for scaling
³¹ of the intensities.

³² 3.5.3 Structure solution

³³ For the determination of the electron density $\rho(\mathbf{r})$, where \mathbf{r} is the positional vector,
³⁴ from the diffraction images by Fourier transformation two terms are necessary as

coefficients; the *structure factor amplitudes*, $F_{\text{obs}}(\mathbf{h})$ and the *phase angles* or *phases*, $\alpha(\mathbf{h})$, where \mathbf{h} is the reciprocal index vector. The structure factor amplitudes can be directly determined from the measured and corrected diffraction intensities of each spot. However, the phase information is lost during the detection of the diffracted photons and there is no direct way to determine the phases. This constitutes the so-called *phase problem*. Thus, additional phasing experiments are necessary in order to obtain the phases. A variety of phasing experiments are available, which include *marker atom substructure methods*, *density modification* and *molecular replacement* (MR) techniques [30]. Phases of the structures herein were exclusively determined by MR [27, 28].

MR was performed using the software *Phaser* [18, 19], which is included in the CCP4-Suite [37]. A previously published PFOMT structure (PDB-code: 3C3Y [15]) was used as a template during MR procedure for the PFOMT structure solution. For the MR of the lysozyme structure the PDB-entry XXXX was used.

BWEIGEL: Lysozym struktur

3.5.4 Model building, refinement and validation

Macromolecular model building and manipulation, as well as real space refinement and Ramachandran idealization were performed using the Crystallographic Object-Oriented Toolkit (*Coot*) software [6]. Structure refinement was done using the software REFMAC5 [21, 35] as part of the CCP4-suite or the Python-based Hierarchical Environment for Integrated Xtallography (PHENIX) [1]. Validation of the structures was carried out using the web service MolProbity (<http://molprobity.biochem.duke.edu/>) [4]. Structure visualization and the preparation of figures was performed using PyMOL (Schrödinger, New York, USA).

3.5.5 *In silico* substrate docking

In silico molecular docking studies were performed using the AutoDock Vina 1.1.2 or AutoDock 4.2.6 software in combination with the AutoDockTools-Suite (<http://autodock.scripps.edu/>) [9, 20, 34]. Substrates were docked into the PFOMT structure with the PDB-code 3C3Y. The grid box, which determines the search space, was manually assigned to center at 1.581, 5.196, 25.718 (x,y,z) and had size of 22, 20, 25 Å (x, y, z)). The exhaustiveness of the global search for AutoDock Vina was set to 25, whereas the rest of the input parameters were kept at their defaults.

3.6 Analytics

3.6.1 In vitro determination of glucose

The glucose concentration in clarified, aqueous samples was determined by a modified version of the glucose assay kit procedure provided by Sigma-Aldrich [32]. Glucose oxidase (GOD) oxidizes D-glucose to gluconic acid, whereby hydrogen peroxide is produced. The hydrogen peroxide can be detected and quantified by horseradish peroxidase (HRP), which reduces the produced H_2O_2 and thereby oxidizes its chromogenic substrate *o*-dianisidine. The oxidized form of *o*-dianisidine can then be measured photospectrometrically [5].

The methodology employs a coupled photospectrometric assay using GOD and HRP with *o*-dianisidine as reporter substrate. The assay was prepared in MTP-format. A reaction solution containing 12.5 U/ml GOD, 2.5 U/ml HRP and 0.125 mg/ml *o*-dianisidine dihydrochloride in 50 mM sodium acetate pH 5.1 was prepared.

Sample solutions from culture supernatants were typically diluted in 9 volumes of water. The reaction was started, by adding 50 μ l reaction solution to 25 μ l of sample and was incubated at 37 °C and 200 rpm for 30 min in a shaking incubator. 50 μ l 6 M sulfuric acid was added to stop the reaction and achieve maximum color development (full oxidation of any *o*-dianisidine charge transfer complexes).

The developed pink color was measured at 540 nm in a MTP-reader. A calibration curve of a standard D-glucose solutions (0 to 100 μ g/ml), that was always part of the experiments, was used to quantify the sample measurements.

3.6.2 HPLC measurements




Figure 3.1.: GOD assay

¹4 **Evaluation of PFOMT towards** ²**the acceptance of long-chain SAM** ³**analogues**

⁴4.1 **Introduction**

⁵4.2 **Substrate binding studies using ITC**

⁶4.3 **Determination of the structure of *apo*-PFOMT**

⁷4.3.1 **PFOMT activity in deep eutectic solvents (DES) / Solubility- ⁸enhancing effects of DES**

⁹vielleicht eigenes kapitel DES?

¹⁰4.4 **Study of variants for long-chain alkylations**

¹¹4.4.1 **PFOMT-Paper (DIM)**

¹²4.4.2 **Dockings???**

¹³4.5 **Colclusion/Discussion**

¹ 5 Enzymatic methylation of Non- ² catechols

³ 5.1 Introduction

⁴ Non-catechols in nature (biosynthesis, mode of action?), chemical methylation???

⁵ 5.2 SOMT-2

⁶ 5.2.1 In vivo methylation studies using *N. benthamiana*

⁷ 5.2.2 In vivo studies in *E. coli*

⁸ 5.2.3 In vitro studies using recombinantly produced SOMT-2

⁹ 5.3 PFOMT

¹⁰ 5.3.1 Acidity and Nucleophilicity of phenolic hydroxyl-groups

¹¹ 5.3.2 pH-Profiles of PFOMT-catalysis

¹² 5.3.3 Influence of Mg^{2+} on PFOMT activity

¹³ 5.4 Consensus or Bioinformatic points-of-view
¹⁴ (COMT)???

¹⁵ 5.5 Conclusion/Discussion

¹ **6 Development of an whole cell** ² **methyl transferase screening sys-** ³ **tem**

⁴ **6.1 Introduction**

⁵ **6.2 Theoretical considerations / design of system**

⁶ **6.3 Detectability of *S*-adenosyl-L-homocysteine** ⁷ **(SAH)**

⁸ *S*-adenosyl-L-methionine (SAM)

⁹ **6.4 Usage of the *lsr*-promoter for true autoinduc-** ¹⁰ **tion**

¹¹ **6.5 Conclusion/Discussion**

¹ **7 DES in protein crystallography**

² **7.1 Introduction**

³ **7.2 Solubility enhancement of hydrophobic substances by addition of DES** ⁴

⁵ **7.3 Enzymatic *O*-methylation in DES**

⁶ **7.4 DES as precipitants in protein crystallization**

⁷ **7.5 Conclusion/Discussion**

8 Acknowledgements

Quisque ullamcorper placerat ipsum. Cras nibh. Morbi vel justo vitae lacus tincidunt
ultrices. Lorem ipsum dolor sit amet, consectetur adipiscing elit. In hac habitasse
platea dictumst. Integer tempus convallis augue. Etiam facilisis. Nunc elementum
fermentum wisi. Aenean placerat. Ut imperdiet, enim sed gravida sollicitudin,
felis odio placerat quam, ac pulvinar elit purus eget enim. Nunc vitae tortor. Proin
tempus nibh sit amet nisl. Vivamus quis tortor vitae risus porta vehicula.
Fusce mauris. Vestibulum luctus nibh at lectus. Sed bibendum, nulla a faucibus
semper, leo velit ultricies tellus, ac venenatis arcu wisi vel nisl. Vestibulum diam.
Aliquam pellentesque, augue quis sagittis posuere, turpis lacus congue quam,
in hendrerit risus eros eget felis. Maecenas eget erat in sapien mattis porttitor.
Vestibulum porttitor. Nulla facilisi. Sed a turpis eu lacus commodo facilisis. Morbi
fringilla, wisi in dignissim interdum, justo lectus sagittis dui, et vehicula libero dui
cursus dui. Mauris tempor ligula sed lacus. Duis cursus enim ut augue. Cras ac
magna. Cras nulla. Nulla egestas. Curabitur a leo. Quisque egestas wisi eget nunc.
Nam feugiat lacus vel est. Curabitur consectetur.



Appendix

1

2

¹A Figures




Figure A.1.: Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem.

B Tables

Table B.1.: Overview over the constructs produced for the present thesis. Each step during the production of the construct is given in the workflow steps column. Primers (*italic font*) or restriction sites used during each step are displayed in parenthesis.

construct name	description	entry constructs	destination	workflow steps (primers/cloning sites)
pBEW101	lsrA promoter pBEW102 with BamHI cloning site rhaP _{BAD} promoter	pBEW102 pBEW4b	pBEW103	amplification (<i>pRha1.fw/rv</i>), cloning (BglII, BamHI)
pBEW102				
pBEW103				
pBEW104				
pBEW106	pICH413038-somt	pET28MC-somt	pICH413038	amplification (<i>somt1/2/3/4</i>), golden gate cloning (Bpil)
pBEW107		pICH51266, pBEW106, pICH41421	pICH75044	golden gate cloning (BsaI)
pBEW1a				
pBEW1b				
pBEW2a				
pBEW2b				
pBEW3a				
pBEW3b				
pBEW4a				
pBEW4b				
pET28-pfomt	<i>pfomt</i> gene in pET-28a(+), endogenous NdeI site removed	pQE30-pfomt	pET-28a(+)	mutagenesis (<i>pfomt1.fw/rv</i>), amplification (<i>pfomt2.fw/rv</i>), cloning (NdeI, EcoRI)
pET20-somt	N-terminal pelB-tag fusion for periplasmic expression		pET20-b(+)	
pET28-somt			pET28-a(+)	
pET28MC-somt	N-terminal Trx-tag fusion N-terminal GST-tag fusion added BglII site pUC19 derivative with lsrA promoter	pUC19 lsr-XX-DAS	pET-32a(+)	mutagenesis (<i>pUC1.fw/rv</i>) cloning (NdeI, BglII)
pET32-somt			pET-41a(+)	
pET41-somt			-	
pUC19*			pUC19*	
pUCB1				
pUCB1-sfGFP-DAS+4				

¹ **C Affidavit**

² I hereby declare that this document has been written only by the undersigned and
³ without any assistance from third parties. Furthermore, I confirm that no sources
⁴ have been used in the preparation of this document other than those indicated in
⁵ the thesis itself.

⁶ Date:....., Location:....., Signature:.....

Bibliography

- [1] Paul D. Adams et al. “PHENIX: A comprehensive Python-based system for macromolecular structure solution”. en. In: *Acta Crystallographica Section D: Biological Crystallography* 66.2 (Feb. 2010), pp. 213–221.
- [2] Agilent Technologies. *QuikChange II Site-Directed Mutagenesis Kit: Instruction Manual*. 2011.
- [3] Frederick M Ausubel et al. “Current Protocols in Molecular Biology”. In: (2008), p. 23.
- [4] Vincent B Chen et al. “MolProbity: all-atom structure validation for macromolecular crystallography.” In: *Acta crystallographica. Section D, Biological crystallography* 66.Pt 1 (Jan. 2010), pp. 12–21.
- [5] Al Claiborne and Irwin Fridovich. “Chemical and Enzymatic Intermediates in the Peroxidation of o-Dianisidine by Horseradish Peroxidase. 1. Spectral Properties of the Products of Dianisidine Oxidation”. In: *Biochemistry* 18 (1979), pp. 2324–2329.
- [6] P. Emsley et al. “Features and development of Coot”. In: *Acta Crystallographica Section D: Biological Crystallography* 66.4 (2010), pp. 486–501.
- [7] Carola Engler, Romy Kandzia, and Sylvestre Marillonnet. “A one pot, one step, precision cloning method with high throughput capability”. In: *PLoS ONE* 3.11 (Jan. 2008), e3647.
- [8] Philip Evans. “Scaling and assessment of data quality”. In: *Acta Crystallographica Section D: Biological Crystallography* 62.1 (Jan. 2006), pp. 72–82. arXiv: *S0907444905036693* [doi:10.1107].
- [9] Ruth Huey et al. “A semiempirical free energy force field with charge-based desolvation.” In: *Journal of computational chemistry* 28.6 (Apr. 2007), pp. 1145–52.

- [10] Mwafaq Ibdah et al. "A Novel Mg²⁺-dependent O-Methyltransferase in the Phenylpropanoid Metabolism of *Mesembryanthemum crystallinum*". In: *Journal of Biological Chemistry* 278.45 (Nov. 2003), pp. 43961–43972.
- [11] Wolfgang Kabsch. "Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants". In: *Journal of Applied Crystallography* 26.pt 6 (Dec. 1993), pp. 795–800.
- [12] Wolfgang Kabsch. "Integration, scaling, space-group assignment and post-refinement". In: *Acta Crystallographica Section D: Biological Crystallography* 66.2 (Feb. 2010), pp. 133–144.
- [13] Wolfgang Kabsch. "Xds". In: *Acta Crystallographica Section D: Biological Crystallography* 66.2 (Feb. 2010), pp. 125–132.
- [14] Youichi Kondou et al. "cDNA Libraries". In: *Methods in Molecular Biology* 729 (2011), pp. 183–197.
- [15] Jakub G. Kopycki et al. "Biochemical and Structural Analysis of Substrate Promiscuity in Plant Mg²⁺-Dependent O-Methyltransferases". In: *Journal of Molecular Biology* 378.1 (Apr. 2008), pp. 154–164.
- [16] Ulrich K Laemmli. "Cleavage of structural proteins during the assembly of the head of bacteriophage T4." In: *Nature* 227.5259 (1970), pp. 680–685.
- [17] Savvas C Makrides and Savvas C Makrides. "Strategies for Achieving High-Level Expression of Genes in *Escherichia coli*". In: *Microbiological reviews* 60.3 (1996), pp. 512–538.
- [18] Airlie J. McCoy. "Solving structures of protein complexes by molecular replacement with Phaser". In: *Acta Crystallographica Section D: Biological Crystallography* 63.1 (Jan. 2006), pp. 32–41.
- [19] Airlie J. McCoy et al. "Phaser crystallographic software". In: *Journal of Applied Crystallography* 40.4 (Aug. 2007), pp. 658–674.
- [20] Garrett M Morris et al. "AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility." In: *Journal of computational chemistry* 30.16 (Dec. 2009), pp. 2785–91.
- [21] Garib N. Murshudov, Alexei a. Vagin, and Eleanor J. Dodson. "Refinement of macromolecular structures by the maximum-likelihood method". In: *Acta Crystallographica Section D: Biological Crystallography* 53.3 (May 1997), pp. 240–255.
- [22] Janet Newman. "Novel buffer systems for macromolecular crystallization". In: *Acta Crystallographica Section D: Biological Crystallography* 60.3 (2004), pp. 610–612.

- [23] Ira Palmer and Paul T. Wingfield. “Preparation and extraction of insoluble (Inclusion-body) proteins from *Escherichia coli*”. In: *Current Protocols in Protein Science* 1.SUPPL.70 (Nov. 2012), Unit6.3.
- [24] Harold R. Powell. “The Rossmann Fourier autoindexing algorithm in MOS-FLM”. In: *Acta Crystallographica Section D: Biological Crystallography* 55.10 (1999), pp. 1690–1695.
- [25] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing. Vienna, Austria, 2015.
- [26] Randy J. Read. “Pushing the boundaries of molecular replacement with maximum likelihood.” en. In: *Acta Crystallographica. Section D: Biological crystallography* 57.Pt 10 (Jan. 2001), pp. 1373–1382.
- [27] M. G. Rossmann and D. M. Blow. “The detection of sub-units within the crystallographic asymmetric unit”. In: *Acta Crystallographica* 15.1 (Jan. 1962), pp. 24–31.
- [28] Michael G. Rossmann. “Molecular replacement - Historical background”. In: *Acta Crystallographica - Section D Biological Crystallography* 57.10 (Sept. 2001), pp. 1360–1366.
- [29] Rainer Rudolph and Hauke Lilie. “In vitro folding of inclusion body proteins”. In: *FASEB Journal* 10 (1996), pp. 49–56.
- [30] Bernhard Rupp. *Biomolecular Crystallography: Principles, Practice, and Application to Structural Biology*. 1st ed. New York: Garland Science, 2009, p. 800.
- [31] J Sambrook and D W Russell. *Molecular Cloning: A Laboratory Manual*. 3rd ed. Cold Spring Harbor (NY, USA): Cold Spring Harbor Laboratory Press, 2001.
- [32] Sigma-Aldrich. *Technical Bulletin no. 2003-03: freezing of microbial samples prior to testing*. Parenteral Drug Association. 2003.
- [33] F William Studier. “Protein production by auto-induction in high density shaking cultures.” In: *Protein expression and purification* 41.1 (May 2005), pp. 207–234. arXiv: NIHMS150003.
- [34] Oleg Trott and Arthur J Olson. “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.” In: *Journal of computational chemistry* 31.2 (Jan. 2010), pp. 455–61.
- [35] Alexei a. Vagin et al. “REFMAC5 dictionary: Organization of prior chemical knowledge and guidelines for its use”. en. In: *Acta Crystallographica Section D: Biological Crystallography* 60.12 I (Nov. 2004), pp. 2184–2195.

- ¹ [36] Thomas Vogt. “Regiospecificity and kinetic properties of a plant natural
² product O-methyltransferase are determined by its N-terminal domain”. In:
³ *FEBS Letters* 561.1-3 (Mar. 2004), pp. 159–162.
- ⁴ [37] Martyn D. Winn et al. “Overview of the CCP4 suite and current develop-
⁵ ments”. In: *Acta Crystallographica Section D: Biological Crystallography* 67.4
⁶ (Apr. 2011), pp. 235–242.

¹ Acronyms

² **Å** Ångstrom, 0.1 nm

³ **B-PER** bacterial protein extraction reagent

⁴ **CCP4** Collaborative Computational Project No. 4 17, 18

⁵ **CD** circular dichroism 10

⁶ **Coot** Crystallographic Object-Oriented Toolkit 18

⁷ **CV** column volumes

⁸ **DES** deep eutectic solvent, see also NADES 7

⁹ **DTT** dithiothreitol; (2S,3S)-1,4-bis(sulfanyl)butane-2,3-diol

¹⁰ **EDTA** ethylenediaminetetraacetic acid 13, 15, 16

¹¹ **FPLC** fast protein liquid chromatography 16

¹² **GdmCl** guanidinium hydrochloride

¹³ **GOD** glucose oxidase 19, 37

¹⁴ **HEPES** 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid

¹⁵ **HRP** horseradish peroxidase 19

¹⁶ **IB** inclusion body 15, 16

¹⁷ **IMAC** immobilized metal affinity chromatography

¹⁸ **IPB** Leibniz-Institute of Plant Biochemistry

¹⁹ **IPTG** isopropyl-D-thiogalactopyranosid 12, 15

²⁰ **LB** lysogeny broth 12, 14, 15

²¹ **MES** 2-(N-morpholino)ethanesulfonic acid

²² **MLU** Martin-Luther-Universität

²³ **MMT** L-malic acid/MES/Tris 6

²⁴ **MR** molecular replacement

- ¹ **MTP** micro-titer plate 16, 17, 19, 37
- ² **MW** molecular weight 14
- ³ **MWCO** molecular weight cut-off
- ⁴ **NADES** natural deep eutectic solvent vii, 7, 35
- ⁵ **NPS** nitrogen, phosphate, sulfate buffer
- ⁶ **NTA** nitrilo triacetic acid 16
- ⁷ **PAGE** polyacrylamide gel electrophoresis 12–14
- ⁸ **PBS** phosphate buffered saline 13
- ⁹ **PCR** polymerase chain reaction 11
- ¹⁰ **PDB** Protein Data Base 18
- ¹¹ **PFOMT** phenylpropanoid and flavonoid O-methyl transferase 14, 15, 17, 18, 37
- ¹² **PHENIX** Phyton-based Hierarchial Environment for Integrated Xtallography 18
- ¹³ **RT** room temperature 13, 14
- ¹⁴ **SAH** S-adenosyl-L-homocysteine 17
- ¹⁵ **SAM** S-adenosyl-L-methionine 23
- ¹⁶ **SDS** sodium dodecylsulfate 7, 12–14
- ¹⁷ **SOMT-2** soy O-methyl transferase 15
- ¹⁸ **TB** terrific broth 12
- ¹⁹ **TCA** trichloro acetic acid 12–14
- ²⁰ **Ti-plasmid** tumor inducing plasmid 8, 37
- ²¹ **Tris** tris(hydroxymethyl)-aminomethane
- ²² **V** volume
- ²³ **ZYP** N-Z-amine, yeast extract, phosphate 14, 15, 37

¹ Glossary

² **GOD** Glucose oxidase is an enzyme.... ³⁵

³ **MTP** Micro-titer plate. Small format rectangular plastic plate containing wells
⁴ to allow for storage of multiple small samples or the containment multiple
⁵ simultaneous reactions. Typical sizes include 24, 96 and 384-wells ³⁶

⁶ **PFOMT** Phenylpropanoid and flavonoid O-methyl transferase from *Mesembryan-*
⁷ *themum crystallinum*, which was first described by Ibdah et al. in 2003 [10]
⁸ ³⁶

⁹ **Ti-plasmid** Commonly found plasmids in *A. tumefaciens* and *A. rhizogenes* that
¹⁰ confer virulence ³⁶

¹¹ **ZYP-5052** Autoinduction medium developed by Studier [33]. The naming stems
¹² from the components N-Z-amine, yeast extract and phosphate. The numbering
¹³ designates the composition; e.g. 5052 refers to 0.5 % glycerol, 0.05 % glucose and
¹⁴ 0.2 % lactose. ³⁶